Man Group plc Takes Position in Vaxcyte, Inc. $PCVX

Man Group plc acquired a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 81,632 shares of the company’s stock, valued at approximately $4,745,000.

Several other institutional investors also recently bought and sold shares of PCVX. NEXTBio Capital Management LP acquired a new stake in Vaxcyte in the 4th quarter valued at $4,406,000. Norges Bank acquired a new position in shares of Vaxcyte in the 4th quarter valued at approximately $56,703,000. Candriam S.C.A. bought a new position in Vaxcyte during the 1st quarter valued at $18,306,000. Bank of America Corp DE lifted its position in shares of Vaxcyte by 73.4% during the first quarter. Bank of America Corp DE now owns 1,216,843 shares of the company’s stock worth $70,711,000 after purchasing an additional 515,209 shares during the last quarter. Finally, Elmind Capital LP bought a new position in Vaxcyte during the 4th quarter worth approximately $13,450,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Vaxcyte Stock Performance

Shares of PCVX stock opened at $59.83 on Monday. Vaxcyte, Inc. has a 52-week low of $30.32 and a 52-week high of $65.00. The firm has a fifty day moving average of $57.48 and a 200-day moving average of $55.99. The stock has a market cap of $8.90 billion, a price-to-earnings ratio of -7.84 and a beta of 1.23.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.06) by $0.09. During the same quarter in the prior year, the firm earned ($1.22) EPS. On average, sell-side analysts predict that Vaxcyte, Inc. will post -7.6 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Zacks Research raised shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Wall Street Zen raised shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $86.00.

Insider Transactions at Vaxcyte

In other news, COO Jim Wassil sold 2,250 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $53.86, for a total value of $121,185.00. Following the transaction, the chief operating officer owned 157,541 shares of the company’s stock, valued at approximately $8,485,158.26. This trade represents a 1.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $53.89, for a total value of $538,900.00. Following the completion of the transaction, the chief financial officer owned 105,176 shares in the company, valued at $5,667,934.64. This represents a 8.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 118,396 shares of company stock valued at $6,459,390 in the last three months. Company insiders own 3.30% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.